Cytokinetics, Inc. : Cytokinetics to Present at 25th Annual Roth Conference
South San Francisco, CA, March 11, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that Robert I. Blum, President and Chief Executive
Officer, is scheduled to present a corporate update at the 25^th Annual Roth
Conference on Monday, March 18, 2013 at 9:00 AM Pacific Time in Salon 5 of the
Ritz Carlton in Laguna Niguel, California.
Interested parties may access the live webcast of this presentation by
visiting the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The webcast replay of the presentation will be archived
on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment
for diseases and conditions associated with aging, muscle wasting or
neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II
clinical trials program and has been granted orphan drug designation and fast
track status by the U.S. Food and Drug Administration and orphan medicinal
product designation by the European Medicines Agency for the potential
treatment of amyotrophic lateral sclerosis, a debilitating disease of
neuromuscular impairment in which treatment with tirasemtiv produced
potentially clinically relevant pharmacodynamic effects in Phase II trials.
All of these drug candidates have arisen from Cytokinetics' muscle biology
focused research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a fundamental
role within every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates
may have unexpected adverse side effects or inadequate therapeutic efficacy.
For further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics' filings with
the Securities and Exchange Commission.
Joanna (Jodi) L. Goldstein
Manager, Corporate Communications and Marketing
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.